How big is X4 Pharmaceuticals, Inc.?

As of Jun 18, X4 Pharmaceuticals, Inc. has a market capitalization of 15.86 million and reported net sales of 31.36 million and net profit of 14.59 million over the latest four quarters.

As of Jun 18, X4 Pharmaceuticals, Inc. has a market capitalization of 15.86 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 31.36 million, while the sum of net profit for the same period is 14.59 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 22.15 million and total assets amounting to 146.45 million.

What does X4 Pharmaceuticals, Inc. do?

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases, including primary immunodeficiencies and cancer. As of March 2025, it has a market cap of $15.86 million and reported net sales of $29 million with no net profit.

Overview: <BR>X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare diseases, including primary immunodeficiencies and cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 29 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 15.86 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.44 <BR>Return on Equity: -46.83% <BR>Price to Book: 0.69<BR><BR>Contact Details: <BR>Address: 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA : 02134 <BR>Tel: ['1 857 5298300', '1 875 3411043'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.x4pharma.com/

Should I buy, sell or hold X4 Pharmaceuticals, Inc.?

Who are in the management team of X4 Pharmaceuticals, Inc.?

As of March 2022, the management team of X4 Pharmaceuticals, Inc. includes Independent Chairman Mr. Michael Wyzga, CEO Dr. Paula Ragan, Directors Ms. Alison Lawton, Dr. Rene Russo, Independent Directors Mr. William Aliski, Dr. Gary Bridger, and Mr. David McGirr. They oversee the company's strategic direction and operations.

As of March 2022, the management team of X4 Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Michael Wyzga, who serves as the Independent Chairman of the Board.<BR>- Dr. Paula Ragan, who is the President, Chief Executive Officer, Corporate Secretary, and a Director.<BR>- Ms. Alison Lawton, who is a Director.<BR>- Dr. Rene Russo, who is also a Director.<BR>- Mr. William Aliski, who serves as an Independent Director.<BR>- Dr. Gary Bridger, who is another Independent Director.<BR>- Mr. David McGirr, who is also an Independent Director. <BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is X4 Pharmaceuticals, Inc. overvalued or undervalued?

As of August 8, 2025, X4 Pharmaceuticals, Inc. has shifted from an attractive to a risky valuation grade due to overvaluation and poor financial metrics, including a Price to Book Value of 1.08 and a ROCE of -878.57%, alongside significant underperformance against the S&P 500 with a year-to-date return of -85.28%.

As of 8 August 2025, the valuation grade for X4 Pharmaceuticals, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued, particularly given its troubling financial metrics, including a Price to Book Value of 1.08, an EV to Sales ratio of 0.47, and an alarming ROCE of -878.57%. <BR><BR>In comparison to its peers, X4 Pharmaceuticals shows a less favorable position, with Foghorn Therapeutics, Inc. having a more negative EV to EBITDA of -1.4807 and Invivyd, Inc. at -1.7450. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -85.28% compared to the index's 12.22%, reinforcing the perception of overvaluation amidst its financial struggles.

Is X4 Pharmaceuticals, Inc. technically bullish or bearish?

As of August 29, 2025, X4 Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -85.28%.

As of 29 August 2025, the technical trend for X4 Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the RSI is bearish for both weekly and monthly periods. Moving averages are showing a mildly bearish trend on the daily timeframe. Overall, the indicators suggest a mixed outlook, with the weekly Bollinger Bands and KST being mildly bullish, while the monthly Bollinger Bands and KST are bearish. <BR><BR>In terms of performance, X4 Pharmaceuticals has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date return of -85.28% versus the S&P 500's 12.22%. This stark contrast highlights the current bearish sentiment surrounding the stock.